Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
Conditions
Interventions
Ruxolitinib Cream
Vehicle Cream
Locations
107
United States
Investigative Site US257
Birmingham, Alabama, United States
Investigative Site US218
Birmingham, Alabama, United States
Investigative Site US239
Montgomery, Alabama, United States
Investigative Site US215
Phoenix, Arizona, United States
Investigative Site US261
Phoenix, Arizona, United States
Investigative Site US240
Tucson, Arizona, United States
Start Date
June 12, 2025
Primary Completion Date
October 9, 2026
Completion Date
July 11, 2027
Last Updated
April 8, 2026
NCT06921850
NCT05889182
NCT06993233
NCT06888193
NCT07316192
NCT06768671
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions